Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03832062
Other study ID # CCR 4838
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 10, 2018
Est. completion date September 30, 2025

Study information

Verified date February 2024
Source Royal Marsden NHS Foundation Trust
Contact Samra Turajlic
Phone 0207 811 8576
Email Samra.Turajlic@rmh.nhs.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.


Description:

In order to establish the feasibility of homogenization as a potential companion diagnostic tool, our study aims to 1) evaluate how many surgical cases have left over tissue amenable to homogenization and 2) pilot homogenization across multiple tumour types. The molecular profile of the homogenate will be compared to that obtained from the diagnostic specimen using next generation sequencing techniques.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date September 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Leftover formalin-fixed tissue (ie that would be otherwise discarded by histopathology) from cancer surgery. 2. Tissues for Research consent has been provided. 3. Patient age >18yo. 4. Minimum of 1 gram of residual tumour remaining in leftover surgical tissue 5. Minimum of 1 gram of normal tissue present. Exclusion Criteria: 1. Advanced Practitioner in histological dissection deems tumour sample to be inadequate. 2. Leftover surgical tumour tissue greater than 20kg.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Leftover surgical tissue homogenization
Leftover surgical tissue homogenization

Locations

Country Name City State
United Kingdom Royal Marsden Hospital NHS Foundation Trust London

Sponsors (2)

Lead Sponsor Collaborator
Royal Marsden NHS Foundation Trust Ventana Medical Systems

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The percentage of cases from surgical lists with tumour remains greater than 1g across 8 tumour groups Surgical lists will be generated providing cases of all surgeries containing excess tumour tissue. The tissue will be dissected and weighed to determine if tumour tissue available is greater than 1g 24 Months
Secondary Median time (in minutes) required for dissection of the leftover surgical tissue into tumour, tumour-adjacent and normal tissue The time taken to dissected will be documented by recording the start and stop times of the procedure and noting this on a source document 24 Months
Secondary Median time (in minutes) required for the blending (actual homogenization) of each tissue type The time taken to homogenize will be documented by recording the start and stop times of the procedure and noting this on a source document 24 Months
Secondary Difference in molecular profile between the diagnostic block and the homogenized sample. This will be measured by next generation sequencing techniques across the 8 primary tumour types The molecular profile of the diagnostic block will be determined by next generation sequencing and the same will be done with the homogenized sample. This will allow a comparison to be made between the two sample types and determine the difference in molecular profile between the two 24 Months
See also
  Status Clinical Trial Phase
Completed NCT01439152 - Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Phase 1
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Active, not recruiting NCT06015009 - Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers N/A
Active, not recruiting NCT03298100 - Risk Scoring Model for Endometrial Cancer
Recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Not yet recruiting NCT04324320 - Psychological Distress in Outpatient Oncological Rehabilitation
Completed NCT00588289 - Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA N/A
Recruiting NCT06222801 - The 1st Tumor CytokinoTherapy Database (TCTD-1)
Recruiting NCT03831633 - Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients Phase 4
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Recruiting NCT05712174 - A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer Phase 2
Completed NCT03988777 - Magnetic Seed Localisation for Nonpalpable Breast Lesions
Recruiting NCT06031233 - Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie Phase 4
Enrolling by invitation NCT04019119 - Digital Intervention for the Modification of Lifestyles (iGame) N/A
Not yet recruiting NCT05926362 - Capillary-Venous Paired Data Collection
Recruiting NCT05510856 - Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients Phase 4
Recruiting NCT05686213 - ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial Phase 2
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Completed NCT04180306 - PEWS Implementation in an LMIC Setting N/A